Although no clear priority is established between TNF or IL-17 inhibitors, it is recommended that a monoclonal antibody against TNF should be preferred in patients with a history of recurrent uveitis or active IBD, whereas an IL-17 inhibitor may be preferred in patients with significant psoriasis [3]. Here, IL17A is linked to uveitis.